Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment

NACompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2016

Conditions
Systemic Lupus ErythematosusMedication Adherence
Interventions
OTHER

Pharmaceutical Care

"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."

OTHER

Control

The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.

Trial Locations (1)

20.551-030

Reumathology outpatient clinics Pedro Ernesto University Hospital, Rio de Janeiro

All Listed Sponsors
collaborator

Hospital Universitario Pedro Ernesto

OTHER

lead

Oswaldo Cruz Foundation

OTHER

NCT02330250 - Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment | Biotech Hunter | Biotech Hunter